# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-273236
Filing Date
2025-11-10
Accepted
2025-11-10 07:10:45
Documents
68
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | olma-20250930.htm iXBRL | 10-Q | 3220168
2 | EX-31.1 | olma-ex31_1.htm | EX-31.1 | 16907
3 | EX-31.2 | olma-ex31_2.htm | EX-31.2 | 16902
4 | EX-32.1 | olma-ex32_1.htm | EX-32.1 | 14535
| Complete submission text file | 0001193125-25-273236.txt |  | 10249397

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | olma-20250930.xsd | EX-101.SCH | 970070
71 | EXTRACTED XBRL INSTANCE DOCUMENT | olma-20250930_htm.xml | XML | 1988801

Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39712 | Film No.: 251464306
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)